{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-005574","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.723110+00:00","generated_at":"2026-06-29T21:55:00.874297+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aligos Q2 2021 net loss $29.8M; $83.6M stock offering; pipeline advances","bullets":["Net loss $29.8M ($0.79 diluted EPS) vs $20.8M ($7.40) year ago; R&D spend $24.6M.","Cash & investments $190.7M at June 30, 2021, down from $243.5M at Dec 2020.","Gross proceeds of $83.6M from July 2021 follow-on stock offering (4.4M shares at $19.00).","STOPS and CAM programs dosing in CHB cohorts; data expected H1 2022.","CTA filed for ASO ALG-020572; NASH drug ALG-055009 CTA on track for Q3 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-005574","json":"https://secwatch.observer/filing/0001171843-21-005574.json","markdown":"https://secwatch.observer/filing/0001171843-21-005574.md","text":"https://secwatch.observer/filing/0001171843-21-005574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184321005574/0001171843-21-005574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184321005574/f8k_080521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:55:00.874297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}